Suppressive effect of syndecan ectodomains and N-desulfated heparins on osteoclastogenesis via direct binding to macrophage-colony stimulating factor

[1]  R. Reis,et al.  Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders. , 2017, Annual review of biomedical engineering.

[2]  R. Eliakim,et al.  Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease , 2017, Digestive Diseases and Sciences.

[3]  A. Theocharis,et al.  Syndecans – key regulators of cell signaling and biological functions , 2017, The FEBS journal.

[4]  Edwin A. Yates,et al.  Heparan sulfate and heparin interactions with proteins , 2015, Journal of The Royal Society Interface.

[5]  L. Lian,et al.  Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis , 2015, Oncotarget.

[6]  Renato V. Iozzo,et al.  Proteoglycan form and function: A comprehensive nomenclature of proteoglycans , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[7]  G. Blobe,et al.  Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. , 2014, The Journal of clinical investigation.

[8]  J. Kreuger,et al.  Heparan Sulfate Biosynthesis , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  Yuanzhong Chen,et al.  N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells , 2010, BMC Cancer.

[10]  J. Couchman,et al.  Proteoglycans in health and disease: the multiple roles of syndecan shedding , 2010, The FEBS journal.

[11]  C. Chillakuri,et al.  Heparin binding domain in vitronectin is required for oligomerization and thus enhances integrin mediated cell adhesion and spreading , 2010, FEBS letters.

[12]  L. Suva,et al.  Tumor-Derived Syndecan-1 Mediates Distal Cross-Talk with Bone that Enhances Osteoclastogenesis , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  H. Takayanagi,et al.  Ca2+‐NFATc1 signaling is an essential axis of osteoclast differentiation , 2009, Immunological reviews.

[14]  Brian J. Ell,et al.  Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor , 2009, The Journal of experimental medicine.

[15]  J. Couchman.  Faculty Opinions recommendation of Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. , 2009 .

[16]  M. Maeda,et al.  Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin , 2008, The Journal of experimental medicine.

[17]  M. Takami,et al.  Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. , 2007, Bone.

[18]  Mone Zaidi,et al.  Skeletal remodeling in health and disease , 2007, Nature Medicine.

[19]  Jeffrey D. Esko,et al.  Heparan sulphate proteoglycans fine-tune mammalian physiology , 2007, Nature.

[20]  Hyunsook Kim,et al.  Vacuolar-type H+-ATPase-mediated acidosis promotes in vitro osteoclastogenesis via modulation of cell migration. , 2007, International journal of molecular medicine.

[21]  D. Spillmann,et al.  Interactions between heparan sulfate and proteins: the concept of specificity , 2006, The Journal of cell biology.

[22]  Rahul Raman,et al.  Glycomics approach to structure-function relationships of glycosaminoglycans. , 2006, Annual review of biomedical engineering.

[23]  A. Woods,et al.  Syndecan-2 Is Expressed in the Microvasculature of Gliomas and Regulates Angiogenic Processes in Microvascular Endothelial Cells* , 2006, Journal of Biological Chemistry.

[24]  F. Ross.  M‐CSF, c‐Fms, and Signaling in Osteoclasts and their Precursors , 2006, Annals of the New York Academy of Sciences.

[25]  N. Perrimon,et al.  Developmental cell biology: Heparan sulphate proteoglycans: the sweet side of development , 2005, Nature Reviews Molecular Cell Biology.

[26]  Shaun K Olsen,et al.  Structural basis for fibroblast growth factor receptor activation. , 2005, Cytokine & growth factor reviews.

[27]  W. Kett,et al.  Heparan sulfate-protein interactions: therapeutic potential through structure-function insights , 2005, Cellular and Molecular Life Sciences CMLS.

[28]  J. Couchman.  Syndecans: proteoglycan regulators of cell-surface microdomains? , 2003, Nature Reviews Molecular Cell Biology.

[29]  A. Zallone,et al.  Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin , 2003, The Journal of cell biology.

[30]  A. Rapraeger,et al.  Syndecan-1-mediated cell spreading requires signaling by αvβ3 integrins in human breast carcinoma cells , 2003 .

[31]  William C. Parks,et al.  Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.

[32]  J. Epstein,et al.  Soluble syndecan-1 promotes growth of myeloma tumors in vivo. , 2002, Blood.

[33]  C. Page,et al.  Novel drug development opportunities for heparin , 2002, Nature Reviews Drug Discovery.

[34]  J. Esko,et al.  Molecular diversity of heparan sulfate. , 2001, The Journal of clinical investigation.

[35]  Dianjun Cao,et al.  High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity , 2000 .

[36]  M. Salmivirta,et al.  Selectively Desulfated Heparin Inhibits Fibroblast Growth Factor-induced Mitogenicity and Angiogenesis* , 2000, The Journal of Biological Chemistry.

[37]  Masato Kato,et al.  Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 , 1998, Nature Medicine.

[38]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[39]  B. Barlogie,et al.  Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. , 1998, Blood.

[40]  M. Goto,et al.  Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.

[41]  C. Piantadosi,et al.  Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. , 1997, The Journal of pharmacology and experimental therapeutics.

[42]  K. Holme,et al.  Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. , 1996, Glycobiology.

[43]  V. Dixit,et al.  Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. , 1995, Cancer research.

[44]  J. Turnbull,et al.  Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. , 1994, The Journal of biological chemistry.

[45]  A. Lander,et al.  Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. , 1994, The Journal of biological chemistry.

[46]  M. Lyon,et al.  Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.

[47]  J. Turnbull,et al.  Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. , 1992, The International journal of biochemistry.

[48]  M. Trautman,et al.  Syndecan, a cell surface proteoglycan, exhibits a molecular polymorphism during lung development. , 1991, Developmental biology.

[49]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[50]  Y. Tabata,et al.  Enhanced osteogenic activity of bone morphogenetic protein-2 by 2-O-desulfated heparin. , 2012, Acta biomaterialia.

[51]  M. Padrines,et al.  Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. , 2011, European journal of cell biology.

[52]  J. Couchman,et al.  Syndecans in wound healing, inflammation and vascular biology. , 2007, The international journal of biochemistry & cell biology.

[53]  E. Tkachenko,et al.  Syndecans: new kids on the signaling block. , 2005, Circulation research.

[54]  A. Rapraeger,et al.  Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. , 2003, Experimental cell research.

[55]  K. Holme,et al.  Heparin in inflammation: potential therapeutic applications beyond anticoagulation. , 1999, Advances in pharmacology.

[56]  N. Udagawa,et al.  Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. , 1993, The Journal of clinical investigation.

[57]  J. Spring,et al.  Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. , 1992, Annual review of cell biology.

[58]  A. Abdel-Malek.  The Concept of Specificity , 1981 .

[59]  D. R. Coombea,et al.  Heparan sulfate-protein interactions : therapeutic potential through structure-function insights , 2022 .